AURKB

Aurora kinase B

279,766 patent compounds predicted against AURKB, 179,282 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL75540	0.61	17/20
SCHEMBL75557	0.60	17/20
SCHEMBL75538	0.58	17/20
SCHEMBL75731	0.58	17/20
SCHEMBL91082	0.74	16/20
SCHEMBL75628	0.59	16/20
SCHEMBL75558	0.62	15/20
SCHEMBL75629	0.59	15/20
SCHEMBL91083	0.50	15/20
SCHEMBL75631	0.76	13/20
SCHEMBL75584	0.75	13/20
SCHEMBL91085	0.49	13/20
Inamrinone (SCHEMBL44012)	1.00	12/20
SCHEMBL75646	0.61	12/20
SCHEMBL91081	0.61	12/20
SCHEMBL61900	0.56	10/20
SCHEMBL62264	0.51	10/20
SCHEMBL100362	0.54	9/20
SCHEMBL82562	0.39	8/20
SCHEMBL84573	0.52	7/20

Germline variants in AURKB on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full AURKB gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to AURKB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression	PHASE3	RECRUITING
Study of MLN8237 in Combination With Irinotecan and Temozolomide	PHASE1/PHASE2	COMPLETED
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma	PHASE2	COMPLETED
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL	PHASE2	RECRUITING
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma	PHASE1/PHASE2	COMPLETED
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	PHASE1	RECRUITING
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors	PHASE1	COMPLETED
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies	PHASE1	COMPLETED
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer	PHASE1	COMPLETED
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors	PHASE1	COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	PHASE1	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.	nan	RECRUITING
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AURKB binder may also engage these)

Protein	Name	Similarity
Q7YRC6	—	0.999	Q7YRC6 →
Q6NW76	—	0.999	Q6NW76 →
A4IGM9	—	0.998	A4IGM9 →
O70126	—	0.998	O70126 →
AURKC	Aurora kinase C	0.997	landscape →
Q9N0X0	—	0.996	Q9N0X0 →
O55099	—	0.994	O55099 →
Q755C4	—	0.994	Q755C4 →
Q6GPL3	—	0.993	Q6GPL3 →
O59790	—	0.993	O59790 →
Q384J7	—	0.992	Q384J7 →
Q9VKN7	—	0.992	Q9VKN7 →
P10665	—	0.992	P10665 →
Q6PFQ0	—	0.991	Q6PFQ0 →
Q63531	—	0.990	Q63531 →
Q91820	—	0.990	Q91820 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.990	landscape →
P97477	—	0.990	P97477 →
Q6DE08	—	0.989	Q6DE08 →
D7UQM5	—	0.989	D7UQM5 →
P51138	—	0.988	P51138 →
Q6C3J2	—	0.988	Q6C3J2 →
Q8BRK8	—	0.988	Q8BRK8 →
Q21734	—	0.988	Q21734 →
Q66JF3	—	0.988	Q66JF3 →
PHKG2	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	0.988	landscape →
P18654	—	0.988	P18654 →
A5GFW1	—	0.988	A5GFW1 →
Q96QS6	—	0.988	Q96QS6 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.988	landscape →